Clinical Trials Browser

Not yet recruiting × INDUSTRY × Breast Neoplasms × Clear all

NCT07287098 2026-04-17

preEMBER

Phase 2 Not yet recruiting

Breast Neoplasms

NCT02802423 2026-04-13

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

Phase 1/2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07524322 2026-04-13

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Phase 1 Not yet recruiting

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT07340658 2026-04-02

SIE-3

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07383506 2026-03-27

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Phase 1 Not yet recruiting

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT07219797 2026-03-25

Study of Monochromatic X-ray Mammography System

Phase NA Not yet recruiting

Breast Neoplasms

NCT07487519 2026-03-23

Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.

Phase 2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07310420 2026-03-11

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

Phase 1 Not yet recruiting

Breast Neoplasms

NCT07459283 2026-03-10

The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors

Phase EARLY_PHASE1 Not yet recruiting

BreastHead & NeckSarcoma

Breast Neoplasms, Head and Neck Neoplasms, Sarcoma, Thyroid Neoplasms

NCT07459738 2026-03-10

A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07461454 2026-03-10

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07446049 2026-03-03

A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression

Phase 2 Not yet recruiting

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT07427407 2026-02-24

Prospective Ultrasound Data Collection Study for AI-Based Detection of Breast Biopsy Markers

Not yet recruiting

Breast Neoplasms

NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

Phase 3 Not yet recruiting

Breast Neoplasms, Recurrence

NCT07401381 2026-02-10

SIE-1

Phase 1 Not yet recruiting

Breast Neoplasms

NCT07393321 2026-02-06

A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07358377 2026-01-22

To Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects With HR-Positive/HER2-Negative Solid Tumor

Phase 1 Not yet recruiting

Breast Neoplasms

NCT07341737 2026-01-15

SL-28 for Advanced Solid Tumours

Phase 1/2 Not yet recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Intestinal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07336771 2026-01-13

JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT07320521 2026-01-06

A Study to Assess the Mass Balance of [14C]HRS-8080 in Healthy Chinese Postmenopausal Female Subjects.

Phase 1 Not yet recruiting

Breast Neoplasms

NCT07294534 2025-12-19

A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT07260058 2025-12-02

Immune Cell Therapy for Advanced Solid Tumors

Phase 1/2 Not yet recruiting

BreastGastrointestinalThoracic

Breast Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT04982848 2025-11-18

Korea Post Marketing Surveillance (PMS) Study of Talzenna®

Not yet recruiting

Breast Neoplasms

NCT06873191 2025-11-17

A Study to Learn More About Tukysa Once it is Out in the Korean Market

Not yet recruiting

Breast Neoplasms

NCT07117214 2025-08-12

A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers

Phase 1 Not yet recruiting

Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07114679 2025-08-11

MBI-GB-Pilot

Phase NA Not yet recruiting

Breast Neoplasms

NCT07088588 2025-07-28

Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1 Not yet recruiting

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT06835400 2025-07-11

Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07036185 2025-06-25

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors

Phase 1 Not yet recruiting

BreastGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT06309615 2025-05-29

PDxBRUTILITY

Not yet recruiting

Breast Neoplasms

NCT06948539 2025-04-29

To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors

Phase 1 Not yet recruiting

BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Colorectal Neoplasms

NCT06929325 2025-04-16

Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

Phase 3 Not yet recruiting

Breast Neoplasms

NCT06920108 2025-04-09

TRACE4BUS for BI-RADS Classification

Not yet recruiting

Breast Neoplasms

NCT06775236 2025-03-19

Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT06757335 2025-01-03

A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT06619873 2024-10-01

A Phase 1, Randomized, Crossover Study to Evaluate the Relative Bioavailability and Food Effect of HRS-8080 in Healthy Subjects

Phase 1 Not yet recruiting

Breast Neoplasms

NCT06614751 2024-09-27

A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway

Phase 1 Not yet recruiting

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06613373 2024-09-25

An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer

Phase 4 Not yet recruiting

Breast Neoplasms

NCT06561607 2024-08-20

A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Phase 3 Not yet recruiting

Breast Neoplasms

NCT06531486 2024-08-01

A Study of XS-02 Capsules in Patients With Advanced Solid Tumors

Phase 1/2 Not yet recruiting

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT04469127 2024-04-10

Heroine01

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT05370300 2024-03-06

SNAPS Breast Cancer Patient Study Breast Cancer Patients

Not yet recruiting

Breast Neoplasms

NCT06183736 2023-12-27

CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency

Phase 2 Not yet recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Lung Neoplasms, Melanoma, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05769491 2023-03-15

Looking At Triple Negative Breast Cancer Patient Experience Patterns in Medical Trials

Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05491057 2022-08-08

Treatment Patterns of Neratinib in HER2+ EBC in China

Not yet recruiting

Breast Neoplasms